Phase 2 URICO-ICTUS trial confirmed the safety of a single 90-min infusion of 1 g UA administration in 421 patients with AIS treated with rtPA within 4.5 h of symptom onset.[ 79 ] The trial showed an overall nonsignificant 6% absolute increment in the rate of good outcome at follow-up but showed a highly significant reduction in the incidence of early stroke worsening stroke in treated patients.[ 80 ] Preplanned analyses in subgroups of patients more vulnerable to oxidative/nitrosative stress, demonstrated highly significant effects of UA therapy in the primary outcome of URICO-ICTUS (modified Rankin Scale score at day 90).
1
—
—